Pharma Slowly Adapting to Complexities and Challenges of Developing Personalized Medicine

This is the first of a two-part feature on the state of personalized drug development. The first part focuses on the scientific challenges facing the industry. The second part discusses the evolving regulatory and financial environment and recent advances in the field.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
      Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter.